- ￥600 - 3200
- 上海莼试
- CS-01Y65026
- 国产
- 2025年12月01日
8 年钻石会员
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 技术资料
- 库存：
48
- 英文名：
7BIO
- CAS号：
916440-85-2
- 供应商：
上海莼试
- 保存条件：
Store at -20°C
- 规格：
10mg 50mg
商品属性：
产品描述：
分子式:C16H10BrN3O2
分子量:356.2
溶解度:Soluble in ethanol;DMSO
储存条件:Store at -20°C
General tips:For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition:Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request
7-bromoindirubin-3'-oxime (7BIO), a derivative of indirubin, is a caspase independent nonapoptotic cell death inducer [1]. 7-bromoindirubin-3'-oxime is an inhibitor of FLT3, DYRK1A, DYRK2, Aurora B and Aurora C kinases.FLT3 is a cytokine receptor expressed on the surface of many hematopoietic progenitor cells. Signalling of FLT3 is important for the normal development of haematopoietic stem cells and progenitor cells. DYRK1A and DYRK2 have been involved in catalyzing its autophosphorylation on serine/threonine and tyrosine residues and play a significant role in a signaling pathway regulating cell proliferation. Aurora kinases are serine/threonine kinases which are essential for cell proliferation and cellular division by controlling chromatid segregation.7-bromoindirubin-3'-oxime (7BIO) showed a marginal inhibitory activity towards CDKs and GSK-3. 7BIO triggered a rapid cell death process distinct from apoptosis. 7BIO induced the appearance of large pycnotic nuclei, without classical features of apoptosis such as chromatin condensation and nuclear fragmentation. 7BIO-induced cell death was not accompanied by cytochrome c release neither by any measurable effector caspase activation. 7BIO triggered the activation of non-apoptotic cell death, possibly through necroptosis or autophagy. 7BIO inhibited FLT3, the dual-specificity tyrosine phosphorylation-regulated kinases, DYRK1A and DYRK2 with the IC50 values of 0.34 μM, 1.9 and 1.3 μM, respectively [2]. 7BIO also inhibited the activity of Aurora B and C kinases with IC50 values of 4.6 and 0.7 μM, respectively [3].References:[1] Ribas J, Bettayeb K, Ferandin Y, et al. 7-Bromoindirubin-3′-oxime induces caspase-independent cell death[J]. Oncogene, 2006, 25(47): 6304-6318.[2] Myrianthopoulos V, Kritsanida M, Gaboriaud-Kolar N, et al. Novel inverse binding mode of indirubin derivatives yields improved selectivity for DYRK kinases[J]. ACS medicinal chemistry letters, 2012, 4(1): 22-26.[3] Myrianthopoulos V, Magiatis P, Ferandin Y, et al. An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted indirubins[J]. Journal of medicinal chemistry, 2007, 50(17): 4027-4037.
注意事项：
抗逆滴加序列
每次向板内滴加抗原时，移液器滴头要与平面45度悬空，不要触碰到孔内的液体，由后向前依次滴加(即浓度由低往高滴加)。
抗感染反应期
抗原抗体在室温20~25℃下，必须反应30min以上，若环境温度低于室温，可将微量反应板置于恒温培养箱中，使二者充分反应。
旅游温度
磷酸盐缓冲液的pH值要在高压灭菌后进行滴定，往往在高压后pH值会有所改变，所以高压后再调一次pH值更为准确。磷酸盐缓冲液一经使用保存期不要超过3周。当pH<5.8时，红细胞会产生自凝现象;当pH>7.8时，图形洗脱加快，易造成肉眼观察产生误差;p H=7.2时，红细胞沉降最充分，图形最清晰。
当滴注 1%红细胞悬液时，应经常摇晃红细胞悬液，使红细胞均匀地分布在磷酸缓冲液中，以防止红细胞下降。
反应时间及温度
加入鸡红血球之后，反应板在室温(20~25℃)静置30~40min，对照孔血球下沉于孔底，即可判定结果。若室温达不到实验要求，需相应调整反应时间。当环境温度低于4℃时，红细胞发生自凝;高于37℃时，会发生反应物分离和红细胞溶血。
使用方法：
1.本蛋白酶抑制剂混合物为100×的储存液，使用时按照1:100的比例加入到裂解液中(例如，1ml裂解液中加入10μl蛋白酶抑制剂混合物)，混匀后即可使用。根据需要，0.5M的EDTA也按照1:100的比例加入到裂解液中（如用于检测金属蛋白酶活性，则不宜添加EDTA）。含有蛋白酶抑制剂混合物的裂解液宜现用现配，不宜配制后冻存待后续使用。
2. 待所需的抑制剂添加完毕混匀后，就可以开始进行哺乳动物组织的裂解和蛋白提取。
公司正在出售的产品：
| 货号 | CS-01Y65026 | 规格 | 10mg 50mg |
| CAS号 | 916440-85-2 | 分子量 | 356.2 |
| 含量 | >98.00% | 别名 | 7-Bromoindirubin-3’-oxime |
| 分子式 | C16H10BrN3O2 | 化学名 | 7-bromo-3-[1,3-dihydro-3-(hydroxyimino)-2H-indol-2-ylidene]-1,3-dihydro-2H-indol-2-one |
| 产地 | 国产 | 用途 | 仅供科研研究实验 |
分子式:C16H10BrN3O2
分子量:356.2
溶解度:Soluble in ethanol;DMSO
储存条件:Store at -20°C
General tips:For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition:Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request
7-bromoindirubin-3'-oxime (7BIO), a derivative of indirubin, is a caspase independent nonapoptotic cell death inducer [1]. 7-bromoindirubin-3'-oxime is an inhibitor of FLT3, DYRK1A, DYRK2, Aurora B and Aurora C kinases.FLT3 is a cytokine receptor expressed on the surface of many hematopoietic progenitor cells. Signalling of FLT3 is important for the normal development of haematopoietic stem cells and progenitor cells. DYRK1A and DYRK2 have been involved in catalyzing its autophosphorylation on serine/threonine and tyrosine residues and play a significant role in a signaling pathway regulating cell proliferation. Aurora kinases are serine/threonine kinases which are essential for cell proliferation and cellular division by controlling chromatid segregation.7-bromoindirubin-3'-oxime (7BIO) showed a marginal inhibitory activity towards CDKs and GSK-3. 7BIO triggered a rapid cell death process distinct from apoptosis. 7BIO induced the appearance of large pycnotic nuclei, without classical features of apoptosis such as chromatin condensation and nuclear fragmentation. 7BIO-induced cell death was not accompanied by cytochrome c release neither by any measurable effector caspase activation. 7BIO triggered the activation of non-apoptotic cell death, possibly through necroptosis or autophagy. 7BIO inhibited FLT3, the dual-specificity tyrosine phosphorylation-regulated kinases, DYRK1A and DYRK2 with the IC50 values of 0.34 μM, 1.9 and 1.3 μM, respectively [2]. 7BIO also inhibited the activity of Aurora B and C kinases with IC50 values of 4.6 and 0.7 μM, respectively [3].References:[1] Ribas J, Bettayeb K, Ferandin Y, et al. 7-Bromoindirubin-3′-oxime induces caspase-independent cell death[J]. Oncogene, 2006, 25(47): 6304-6318.[2] Myrianthopoulos V, Kritsanida M, Gaboriaud-Kolar N, et al. Novel inverse binding mode of indirubin derivatives yields improved selectivity for DYRK kinases[J]. ACS medicinal chemistry letters, 2012, 4(1): 22-26.[3] Myrianthopoulos V, Magiatis P, Ferandin Y, et al. An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted indirubins[J]. Journal of medicinal chemistry, 2007, 50(17): 4027-4037.
注意事项：
抗逆滴加序列
每次向板内滴加抗原时，移液器滴头要与平面45度悬空，不要触碰到孔内的液体，由后向前依次滴加(即浓度由低往高滴加)。
抗感染反应期
抗原抗体在室温20~25℃下，必须反应30min以上，若环境温度低于室温，可将微量反应板置于恒温培养箱中，使二者充分反应。
旅游温度
磷酸盐缓冲液的pH值要在高压灭菌后进行滴定，往往在高压后pH值会有所改变，所以高压后再调一次pH值更为准确。磷酸盐缓冲液一经使用保存期不要超过3周。当pH<5.8时，红细胞会产生自凝现象;当pH>7.8时，图形洗脱加快，易造成肉眼观察产生误差;p H=7.2时，红细胞沉降最充分，图形最清晰。
当滴注 1%红细胞悬液时，应经常摇晃红细胞悬液，使红细胞均匀地分布在磷酸缓冲液中，以防止红细胞下降。
反应时间及温度
加入鸡红血球之后，反应板在室温(20~25℃)静置30~40min，对照孔血球下沉于孔底，即可判定结果。若室温达不到实验要求，需相应调整反应时间。当环境温度低于4℃时，红细胞发生自凝;高于37℃时，会发生反应物分离和红细胞溶血。
使用方法：
1.本蛋白酶抑制剂混合物为100×的储存液，使用时按照1:100的比例加入到裂解液中(例如，1ml裂解液中加入10μl蛋白酶抑制剂混合物)，混匀后即可使用。根据需要，0.5M的EDTA也按照1:100的比例加入到裂解液中（如用于检测金属蛋白酶活性，则不宜添加EDTA）。含有蛋白酶抑制剂混合物的裂解液宜现用现配，不宜配制后冻存待后续使用。
2. 待所需的抑制剂添加完毕混匀后，就可以开始进行哺乳动物组织的裂解和蛋白提取。
公司正在出售的产品：
| Boc-β-HoPro-OH | Ibotenic acid |
| Nav1.7-IN-2 | 人钙粘蛋白相关的神经受1(CNR-1)elisa试剂盒 |
| Dehydro Amlodipine (fumarate) | 人毛细血管扩张性共济失调突变基因(ATM)试剂盒elisa |
| CALP2 TFA | 人特异性巨噬细胞武装因子(SMAF)ELISA试剂盒 |
| AAQ chloride | 人芳香烃受(AhR)检测试剂盒elisa |
| Oxybuprocaine HCl | 人促有丝分裂因子(MF/MPF)试剂盒ELISA |
| γ-Aminobutyric acid | 人转录因子抗-1(ATF-1)ELISA检测试剂盒 |
| Vernakalant Hydrochloride | 人抗鼠抗(HAMA)elisa试剂盒 |
| Mibefradil | 人烟酰胺腺嘌呤二核苷酸磷酸(NADPH)ELISA检测试剂盒 |
| GYKI 52466 dihydrochloride | 人α2纤溶酶抑制物(α2-PI)试剂盒ELISA |
| rac BHFF | 人αN已酰氨基葡糖苷酶(αNAG)ELISA试剂盒 |
| NF 449 | 人α半乳糖基抗(Gal)检测试剂盒elisa |
| Procaine HCl | 7BIO人β内酰胺酶抑制剂(BLI)试剂盒elisa |
| Valganciclovir | 人β萘酚(β-Nph)elisa试剂盒 |
| 人胃动素ELISA试剂盒 | 人免疫核糖核酸(Irna)ELISA检测试剂盒 |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
技术资料暂无技术资料 索取技术资料
7BIO
￥600 - 3200
